eli lilly news - Search News

Novo Nordisk raises expectations for Eli Lilly

Seeking Alpha on MSN · 10h

Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug CagriSema disappointed. Read more here.

YAHOO!Finance · 1d

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Business Insider · 1d

Novo Nordisk's CagriSema Shows Superior, But Lower-than-expected Weight Loss In Obesity; Stock Drops

Novo Nordisk A/S (NVO) announced Friday that its experimental obesity drug CagriSema demonstrated superior weight loss in adults with

Eli Lilly, obstructive sleep apnea and FDA

Hosted on MSN · 1d

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.

FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The Wall Street Journal on MSN · 1d

Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients

Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or tirzepatide, is the first and only prescription medicine for adults suffering from this condition.

9h

Eli Lilly to test weight loss drug Zepbound to treat addiction

Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

1d

Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

GlobalData on MSN1d

FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation

The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...

1d

Zepbound helps shed more weight than Wegovy, Eli Lilly study says

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.

3d

Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Lilly stock caught up in wave of uncertainty

After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ...

1don MSN

Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...

2d

This Is Huge News for Eli Lilly Investors

The hottest area among healthcare investors right now revolves around advancements being made in weight loss. Known as ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results